PL2717873T3 - Pochodne pirazolowe - Google Patents

Pochodne pirazolowe

Info

Publication number
PL2717873T3
PL2717873T3 PL12727632T PL12727632T PL2717873T3 PL 2717873 T3 PL2717873 T3 PL 2717873T3 PL 12727632 T PL12727632 T PL 12727632T PL 12727632 T PL12727632 T PL 12727632T PL 2717873 T3 PL2717873 T3 PL 2717873T3
Authority
PL
Poland
Prior art keywords
pyrazole derivatives
pyrazole
derivatives
Prior art date
Application number
PL12727632T
Other languages
English (en)
Inventor
Guido Galley
Cédric Ghellamallah
Roger Norcross
Philippe Pflieger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2717873T3 publication Critical patent/PL2717873T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL12727632T 2011-06-09 2012-06-06 Pochodne pirazolowe PL2717873T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11169217 2011-06-09
EP12727632.7A EP2717873B1 (en) 2011-06-09 2012-06-06 Pyrazole derivatives
PCT/EP2012/060627 WO2012168260A1 (en) 2011-06-09 2012-06-06 Pyrazole derivatives

Publications (1)

Publication Number Publication Date
PL2717873T3 true PL2717873T3 (pl) 2015-12-31

Family

ID=46298390

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12727632T PL2717873T3 (pl) 2011-06-09 2012-06-06 Pochodne pirazolowe

Country Status (32)

Country Link
US (1) US9073911B2 (pl)
EP (1) EP2717873B1 (pl)
JP (1) JP5914642B2 (pl)
KR (1) KR101574905B1 (pl)
CN (1) CN103596567B (pl)
AR (1) AR088741A1 (pl)
AU (1) AU2012266457B2 (pl)
BR (1) BR112013031324B1 (pl)
CA (1) CA2837255C (pl)
CL (1) CL2013003484A1 (pl)
CO (1) CO6801764A2 (pl)
CY (1) CY1116778T1 (pl)
DK (1) DK2717873T3 (pl)
EA (1) EA024648B1 (pl)
EC (1) ECSP13013072A (pl)
ES (1) ES2546438T3 (pl)
HR (1) HRP20151077T1 (pl)
IL (1) IL229549B (pl)
MA (1) MA35192B1 (pl)
MX (1) MX347239B (pl)
MY (1) MY162160A (pl)
PE (1) PE20140934A1 (pl)
PH (1) PH12013502315A1 (pl)
PL (1) PL2717873T3 (pl)
PT (1) PT2717873E (pl)
RS (1) RS54183B1 (pl)
SG (1) SG195156A1 (pl)
SI (1) SI2717873T1 (pl)
TW (1) TWI440636B (pl)
UA (1) UA110525C2 (pl)
WO (1) WO2012168260A1 (pl)
ZA (1) ZA201308939B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
RU2621050C2 (ru) * 2012-01-12 2017-05-31 Ф. Хоффманн-Ля Рош Аг Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars)
NO2895477T3 (pl) * 2012-09-14 2018-03-31
US9580407B2 (en) * 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
WO2015165085A1 (en) * 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
JP6814814B2 (ja) 2016-03-17 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｔａａｒのアゴニストとしての活性を有する５−エチル−４−メチル−ピラゾール−３−カルボキサミド誘導体
CN118271233A (zh) 2017-04-24 2024-07-02 特沙诺有限公司 尼拉帕利的制造方法
CN112457255B (zh) * 2017-11-08 2022-08-19 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
CN112585128B (zh) * 2018-06-18 2023-02-21 詹森药业有限公司 作为malt1抑制剂的吡唑衍生物
KR102161787B1 (ko) * 2018-07-02 2020-10-06 한국기초과학지원연구원 수면 장애의 예방 또는 치료용 약학적 조성물
WO2020064792A1 (en) 2018-09-27 2020-04-02 F. Hoffmann-La Roche Ag Heterocyclyl compounds for the treatment of autoimmune disease
WO2020175957A1 (ko) * 2019-02-28 2020-09-03 주식회사 마더스제약 피라졸 아마이드 유도체 화합물 및 이의 용도
EP3983386A4 (en) * 2019-05-14 2023-01-11 Metabomed Ltd ACSS2 INHIBITORS AND METHODS OF USE THEREOF
CA3146830A1 (en) * 2019-07-11 2021-01-14 F. Hoffmann-La Roche Ag Process for the preparation of substituted pyrazole derivatives
US20240400577A1 (en) * 2021-07-08 2024-12-05 Vibliome Therapeutics, Llc Modulators of protein kinases
WO2023183444A1 (en) * 2022-03-24 2023-09-28 Vibliome Therapeutics, Llc Modulators of protein kinases
AU2023323858A1 (en) * 2022-08-12 2024-11-21 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide
KR20250176791A (ko) 2024-06-13 2025-12-22 인천대학교 산학협력단 피라졸 유도체를 유효성분으로 포함하는 항노화 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
PT1036065E (pt) 1997-12-04 2004-09-30 Allergan Inc Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US9132136B2 (en) * 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
CN102899314A (zh) 2011-07-29 2013-01-30 江汉大学 一种批量基因克隆的方法

Also Published As

Publication number Publication date
MA35192B1 (fr) 2014-06-02
US20120316172A1 (en) 2012-12-13
IL229549B (en) 2019-06-30
JP2014516066A (ja) 2014-07-07
EP2717873B1 (en) 2015-07-15
ECSP13013072A (es) 2014-01-31
BR112013031324A2 (pt) 2016-11-29
NZ617350A (en) 2016-01-29
ZA201308939B (en) 2014-08-27
MY162160A (en) 2017-05-31
SI2717873T1 (sl) 2015-09-30
WO2012168260A1 (en) 2012-12-13
CL2013003484A1 (es) 2014-08-08
SG195156A1 (en) 2013-12-30
HK1191862A1 (zh) 2014-08-08
DK2717873T3 (en) 2015-07-27
UA110525C2 (ru) 2016-01-12
AU2012266457A1 (en) 2013-11-14
RS54183B1 (sr) 2015-12-31
KR101574905B1 (ko) 2015-12-04
MX2013013853A (es) 2014-01-20
HRP20151077T1 (hr) 2015-11-06
AR088741A1 (es) 2014-07-02
EA024648B1 (ru) 2016-10-31
EA201391787A1 (ru) 2014-04-30
US9073911B2 (en) 2015-07-07
KR20140029517A (ko) 2014-03-10
CA2837255C (en) 2020-10-27
CA2837255A1 (en) 2012-12-13
MX347239B (es) 2017-04-20
TWI440636B (zh) 2014-06-11
IL229549A0 (en) 2014-01-30
PT2717873E (pt) 2015-09-18
CY1116778T1 (el) 2017-03-15
AU2012266457B2 (en) 2016-09-08
CO6801764A2 (es) 2013-11-29
TW201302727A (zh) 2013-01-16
CN103596567A (zh) 2014-02-19
PE20140934A1 (es) 2014-08-06
CN103596567B (zh) 2016-03-16
EP2717873A1 (en) 2014-04-16
JP5914642B2 (ja) 2016-05-11
BR112013031324B1 (pt) 2021-11-03
PH12013502315A1 (en) 2016-05-11
ES2546438T3 (es) 2015-09-23

Similar Documents

Publication Publication Date Title
EP2698368A4 (en) NEW PYRAZOLE DERIVATIVE
SG10201601802YA (en) Dispiropyrrolidine derivatives
ZA201308939B (en) Pyrazole derivatives
ZA201401884B (en) New dihydroquinoline-2-one derivatives
AP2014007372A0 (en) Indazoles
ZA201304282B (en) Pyrazole derivative
SG11201401937YA (en) New aryl-quinoline derivatives
IL247637B (en) History of heteroaryl piperidine
ZA201403000B (en) Azole Derivative
IL229990A0 (en) History of n-oxypyrazolo-triazapine-dione
EP2687531A4 (en) TETRAHYDROCARBOLINE DERIVATIVE
ZA201307404B (en) Pyrazolidin-3-one derivatives
EP2740730A4 (en) DIBENZOOXEPINE DERIVATIVE
IL233001A0 (en) New iso-ergoline histories
EP2703403A4 (en) imidazole
ZA201307179B (en) Azole derivative
SI2766342T1 (sl) Derivati fenil-gvanidina
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
ZA201303800B (en) Pyrazole compounds
ZA201103204B (en) Phenylpyrazole derivatives
GB201219296D0 (en) Pyrazole derivatives
GB201219289D0 (en) Pyrazole derivatives
GB201218245D0 (en) Pyrazole derivatives
ZA201209319B (en) Cyclopropyl-indole derivatives